Sirtuin 1 activator SRT2104 protects Huntington's disease mice

Annals of Clinical and Translational Neurology

Volumn 1, Issue 12, 2014, Pages 1047-1052

  Jiang, Mali ^a   Zheng, Jennifer ^a   Peng, Qi ^a   Hou, Zhipeng ^a   Zhang, Jiangyang ^a   Mori, Susumu ^a   Ellis, James L ^b   Vlasuk, George P ^b   Fries, Harvey ^b   Suri, Vipin ^b   Duan, Wenzhen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; SIRTUIN 1; SRT2104; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED STUDY; DRUG PENETRATION; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; HUNTINGTON CHOREA; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL;

EID: 84938685650     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.135     Document Type: Article

References (19)

1. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10:204–216.
2. Jeong H, Cohen DE, Cui L, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2011;18:159–165.
3. Jiang M, Wang J, Fu J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2011;18:153–158.
4. Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron 2014;81:471–483.
5. Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014;35:146–154.
6. Hubbard BP, Gomes AP, Dai H, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013;339:1216–1219.
7. Lakshminarasimhan M, Curth U, Moniot S, et al. Molecular architecture of the human protein deacetylase Sirt1 and its regulation by AROS and resveratrol. Biosci Rep 2013;33:395–404.
8. Mitchell SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 2014;6:836–843.
9. Graff J, Kahn M, Samiei A, et al. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J Neurosci 2013;33:8951–8960.
10. Ng PY, Bemis JE, Disch JS, et al. The identification of the SIRT1 activator SRT2104 as a clinical candidate. Lett Drug Des Discov 2013;10:793–797.
11. Hoffmann E, Wald J, Lavu S, et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2012;75:186–196.
12. Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2013;7:e51395.
13. Duan W, Guo Z, Jiang H, et al. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 2003;100:2911–2916.
14. Jiang M, Peng Q, Liu X, et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet 2013;22:2462–2470.
15. Cheng Y, Peng Q, Hou Z, et al. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage 2011;56:1027–1034.
16. Parker JA, Arango M, Abderrahmane S, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005;37:349–350.
17. Smith MR, Syed A, Lukacsovich T, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014;23:2995–3007.
18. Rothgiesser KM, Erener S, Waibel S, et al. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 2010;123:4251–4258.
19. Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010;107:7927–7932.